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Purpose: Urinary angiotensinogen has been reported as a marker for the activation of intrarenal 
renin–angiotensin system (RAS) in various kidney diseases. To investigate the importance of 
urinary angiotensinogen in diabetic nephropathy, we compared the urinary levels of angio-
tensinogen, albumin, and α1-microglobulin.
Materials and methods: Japanese patients with type 2 diabetes at various stages of neph-
ropathy (n=85) were enrolled, and we measured albumin/creatinine ratio (ACR) and urinary 
excretion of angiotensinogen and α1-microglobulin. We also compared the clinical data of 
the patients treated with or without angiotensin II receptor blockers or angiotensin-converting 
enzyme inhibitors (RAS inhibitors [+], n=51; RAS inhibitors [−], n=34).
Results: Urinary angiotensinogen levels positively correlated with ACR (r =0.367, P=3.84×10−4) 
and urinary α1-microglobulin (r=0.734, P=1.32 × 10−15), while they negatively correlated with 
estimated glomerular filtration ratio (eGFR) (r=−0.350, P=1.02 × 10−3) and high-density lipo-
protein cholesterol (r=−0.216, P=0.049). Multiple regression analysis was carried out to predict 
urinary angiotensinogen levels by employing eGFR, ACR, and urinary α1-microglobulin as inde-
pendent variables; only urinary α1-microglobulin entered the regression equation at a significant 
level. Although ACR was higher in the RAS inhibitors (+) group, urinary α1-microglobulin and 
angiotensinogen did not show significant increase in the RAS inhibitors (+) group.
Conclusion: Urinary angiotensinogen is well correlated with urinary α1-microglobulin and 
reflected the tubular injuries which may be associated with the intrarenal RAS activation in 
patients with type 2 diabetes.
Keywords: diabetic nephropathy, urinary biomarkers, renin–angiotensin system, 
 angiotensinogen, α1-microglobulin, albumin
Introduction
The role of local renin–angiotensin system (RAS) in kidney tissues in the pathophysiol-
ogy of diabetic nephropathy has been emphasized.1 The hyporeninemic hypoaldoster-
onism observed along with the progression of diabetic nephropathy and the efficacy 
of RAS inhibitors reducing the albuminuria in such patients also supports the notion 
that intrarenal RAS plays an important role in the progression of diabetic  nephropathy. 
Sawaguchi et al2 reported that the baseline urinary excretion of angiotensinogen 
(10–150 µg/gCr) positively correlated with albumin/creatinine ratio (r =0.77, P,0.001) 
and urinary β2-microglobulin (r =0.72, P,0.001) in type 2 diabetes patients with 
normo- and microalbuminuria. Furthermore, urinary angiotensinogen significantly 
correlated with annual decline of estimated glomerular filtration rate (eGFR) (r =−0.51, 
P,0.001), and a higher level of urinary angiotensinogen is a risk for the progression of 
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diabetic nephropathy.2 Most of the clinical studies measuring 
urinary angiotensinogen and albumin levels demonstrated 
the strong correlation between two proteins with comparable 
molecular weight (67 and 65 kDa). Thus, it is still unknown 
whether urinary angiotensinogen is a marker of impairment of 
glomerular permeability like albumin/creatinine ratio (ACR), 
a marker of tubular interstitial injuries or a biomarker for the 
activation of intrarenal RAS in diabetic nephropathy. In this 
study, we measured ACR, urinary α1-microglobulin, and 
urinary angiotensinogen levels in patients with various stages 
of diabetic nephropathy and investigated the clinical signifi-
cance of urinary angiotensinogen in diabetic nephropathy.
Materials and methods
Patients
We recruited Japanese patients with type 2 diabetes (n=85, 
62.9 ± 11.3 years) into this study at Okayama University 
Hospital. The current study is a substudy of the report and 
shared the recruited patients.3 Patients were treated with oral 
hypoglycemic agents (n=48) and insulin (n=49). The patients 
with hypertension (n=59) were treated with angiotensin II 
receptor blockers (ARB; n=49), angiotensin-converting 
enzyme inhibitors (ACEI; n=13), calcium channel blockers 
(n=34), and diuretics (n=11). We compared the clinical data 
of the patients treated with ARB or ACEI (RAS inhibitors 
[+]; n=51) without ARB and ACEI (RAS inhibitors [−]; 
n=34). Dyslipidemia was noted in 53 patients; most of these 
patients were treated with statins (n=45). The patients with 
eGFR ,15 mL/min/1.73 m2 or those undergoing dialysis 
were excluded from the current study. All recruited patients 
with type 2 diabetes agreed to measure urinary levels of 
α1-microglobulin and  angiotensinogen. The study was 
conducted in accordance with the ethical principle of the 
Declaration of Helsinki and was approved by the ethical 
committee of Okayama University Graduate School of 
Medicine, Dentistry, and Pharmaceutical Sciences. Written 
informed consent was obtained from each patient.
Blood sampling and assays
We measured overnight fasting serum levels of total cholesterol 
and low-density lipoprotein (LDL) cholesterol, high-density 
lipoprotein (HDL) cholesterol, triglycerides (Wako L Type 
Triglyceride H; Wako Pure Chemical Industries, Osaka, 
Japan), uric acid,  creatinine (Cr), and urea nitrogen. HbA
1c
 
levels were also measured. Urinary albumin was measured in 
random spot urine samples by standard immunonephelometric 
assay. The urinary ACR was calculated. eGFR was calculated 
by the equation
 eGFR (mL/min/1.73 m2) =194 × Cr−1.094 × age−0.287 (1)
in males and
eGFR (mL/min/1.73 m2) =194 × Cr−1.094 × age−0.287 × 0.739
 (2)
in females. Urinary excretions of α1-microglobulin and 
angiotensinogen were measured with enzyme-linked immu-
nosorbent assay (ELISA) kits; LZ Test Eiken α1-M (Eiken 
Chemical Co, Tokyo, Japan), and Human Total Angio-
tensinogen Assay Kit (Immuno-Biological Laboratories Co, 
Ltd, Fujioka, Gunma, Japan).
Statistical analysis
All data are expressed as mean ± standard deviation values. 
Spearman correlation coefficients were used to evaluate 
whether urinary levels of angiotensinogen correlated with 
various parameters. To determine the variables indepen-
dently associated with urinary levels of angiotensinogen in 
the patients with type 2 diabetes, multiple regression analy-
sis was performed by including eGFR, ACR, and urinary 
α1-microglobulin/creatinine ratio as independent variables. 
Urinary levels of α1-microglobulin, angiotensinogen, and 
various clinical parameters in RAS inhibitors (−) and RAS 
inhibitors (+) groups were compared by Mann–Whitney U 
testing. P-values less than 0.05 were considered statistically 
significant. Statistical analysis was performed with IBM 
SPSS Statistics Base and IBM SPSS Regression (IBM Cor-
poration, Armonk, NY, USA).
Results
Correlation of urinary angiotensinogen 
with urinary α1-microglobulin
The type 2 diabetes patients (n=85) with various albuminuria 
stages (ie, normo [n=36], micro- [n=25], and macroalbu-
minuric [n=24]  stages) were recruited into the study and 
were classified into RAS inhibitors (−) and RAS inhibitors 
(+) groups (Table 1). At each albuminuria stage, we observed 
significantly different serum concentrations of total protein 
(demonstrated by Kruskal–Wallis test) (70.4 ± 4.3 g/L, 
70.7 ± 4.8 g/L, 66.1 ± 6.5 g/L; P=0.003), albumin 
(42.9 ± 2.5 g/L, 41.2 ± 3.2 g/L, 35.7 ± 7.0 g/L; P=1.80 × 10−16), 
creatinine (66.4 ± 13.3 µmol/L, 78.3 ± 26.3 µmol/L, 
144.2 ± 70.3 µmol/L; P=4.86 × 10−10), urea nitrogen 
(5.5 ± 1.5 µmol/L, 7.1 ± 2.7 µmol/L, 10.0 ± 3.8 µmol/L; 
P=5.92 ×  10−8), uric acid (305.8 ±  61.5 µmol/L, 
352.8 ± 96.2 µmol/L, 396.2 ± 68.0 µmol/L; P=9.68 × 10−5), 
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Table 1 Comparison of various parameters in the type 2 diabetes patients (n=85) with normo- (n=36), micro- (n=25), and 
macroalbuminuric (n=24) stages
RAS inhibitors (-) RAS inhibitors (+) Total Mann–Whitney U
Number (male/female) 34 (16/18) 51 (33/18) 85 (49/36)
Age (years ± SD) 63.1 ± 11.7 62.5 ± 11.1 62.9 ± 11.3 0.492
BMI (kg/m2 ± SD) 24.5 ± 4.4 25.1 ± 4.7 24.9 ± 4.6 0.618
SBP (mmHg ± SD) 122.9 ± 13.4 128.3 ± 19.2 126.2 ± 17.3 0.216
DBP (mmHg ± SD) 71.2 ± 10.9 72.8 ± 11.2 72.2 ± 11.1 0.339
HbA1c (% ± SD) 7.27 ± 0.68 7.33 ± 0.98 7.31 ± 0.87 0.974
Total protein (g/L ± SD) 70.1 ± 5.8 68.7 ± 5.1 69.3 ± 5.4 0.339
Albumin (g/L ± SD) 41.4 ± 5.8 39.6 ± 5.0 40.4 ± 5.3 0.032*
Cr (µmol/L ± SD) 81.4 ± 53.9 98.8 ± 50.6 91.9 ± 52.3 0.028*
UN (µmol/L ± SD) 7.0 ± 3.4 7.4 ± 3.2 7.3 ± 3.3 0.418
Uric acid (µmol/L ± SD) 321.3 ± 66.8 360.3 ± 89.8 344.6 ± 83.1 0.034*
T-Cho (mmol/L ± SD) 5.32 ± 1.01 4.77 ± 0.88 4.99 ± 0.97 0.011*
TG (mmol/L ± SD) 1.76 ± 1.07 1.84 ± 1.37 1.81 ± 1.26 0.904
HDL-C (mmol/L ± SD) 1.51 ± 0.45 1.29 ± 0.31 1.38 ± 0.39 0.041*
LDL-C (mmol/L ± SD) 3.03 ± 0.84 2.62 ± 0.74 2.79 ± 0.80 0.024
eGFR (mL/min ± SD) 68.5 ± 20.7 60.2 ± 23.0 63.5 ± 22.4 0.052
ACR (mg/gCr ± SD) 368.2 ± 863.8 489.8 ± 779.8 441.2 ± 812 0.006**
α1-microglobulin (µg/gCr ± SD) 7.26 ± 13.2 9.63 ± 10.6 8.68 ± 11.74 0.306
Angiotensinogen (µg/gCr ± SD) 13.3 ± 27.5 34.6 ± 71.5 26.1 ± 58.8 0.374
Notes: The patients are classified whether they are treated with or without angiotensin receptor blockers or angiotensin-converting enzyme inhibitors. *P,0.05; 
**P,0.01.
Abbreviations: ACR, albumin/creatinine ratio; BMI, body mass index; Cr, serum creatinine; DPB, diastolic blood pressure; eGFR, estimated glomerular filtration ratio; 
HbA1c, hemoglobin A1c; HDL-C, HDL cholesterol; LDL-C, LDL cholesterol; RAS inhibitors (+), patients treated with angiotensin II receptor blockers or angiotensin-
converting enzyme inhibitors; RAS inhibitors (–), patients not treated with angiotensin II receptor blockers or angiotensin-converting enzyme inhibitors; SD, standard 
deviation; SBP, systolic blood pressure; T-Cho, total cholesterol; TG, triglyceride; UN, serum urea nitrogen.
HDL-C (1.49 ± 0.41 mmol/L, 1.35 ± 0.31 mmol/L, 
1.23 ± 0.39 mmol/L; P=0.031), and eGFR (74.5 ± 16.3 mL/min, 
67.9 ± 19.2 mL/min, 42.4 ± 19.0 mL/min; P=6.66 × 10−9). 
Urinary proteins also significantly increased with the pro-
gression of albuminuria stages: ACR (12.7 ± 6.0 mg/gCr, 
114.3 ± 72.6 mg/gCr, 1.424 ± 996 mg/gCr; P=1.81 × 10−16), 
urinary α1-microglobulin (4.24 ±  4.03 µg/gCr, 
6.30 ± 5.12 µg/gCr, 17.83 ± 18.08 µg/gCr; P=8.84 × 10−9), and 
urinary angiotensinogen (6.8 ± 11.6 µg/gCr, 8.5 ± 9.9 µg/gCr, 
73.3 ± 95.2 µg/gCr; P=2.88 × 10−4).
By simple regression analyses of these parameters, 
urinary angiotensinogen levels significantly and positively 
correlated with ACR (r =0.376, P=3.84  × 10−4) and urinary 
α1-microglobulin (r =0.734, P=1.32 × 10−15), while they sig-
nificantly and negatively correlated with eGFR (r =−0.350, 
P=1.02 × 10−3) and HDL-C (r =−0.216, P=0.049) (Table 2 
and Figure 1). We next investigated the correlations of uri-
nary angiotensinogen, ACR, and urinary α1-microglobulin 
in various albuminuria stages. At all three albuminuria 
stages, urinary angiotensinogen levels did not correlate 
with ACR; however, urinary angiotensinogen levels sig-
nificantly and highly correlated with α1-microglobulin 
at the normoalbuminuria stage (r =0.840, P=1.40 × 10−10) 
Table 2 Simple correlation of urinary angiotensinogen with 
various clinical parameters in patients with type 2 diabetes 
(n=85)
Angiotensinogen (μg/gCr)
Age (years) r =−0.040, P=0.713
BMI (kg/m2) r =−0.086, P=0.431
SBP (mmHg) r =−0.033, P=0.764
DBP (mmHg) r =−0.173, P=0.113
HbA1c (%) r =−0.039, P=0.726
Total protein (g/L) r =−0.107, P=0.338
Albumin (g/L) r =−0.165, P=0.136
Cr (µmol/L) r =0.243, P=0.025*
UN (µmol/L) r =0.362, P=0.001**
Uric acid (µmol/L) r =0.081, P=0.462
T-Cho (mmol/L) r =−0.109, P=0.325
TG (mmol/L) r = 0.012, P=0.911
HDL-C (mmol/L) r =−0.216, P=0.049*
LDL-C (mmol/L) r =−0.051, P=0.646
eGFR (mL/min) r =−0.350, P=1.02 × 10−3**
ACR (mg/gCr) r =0.376, P=3.84 × 10−4**
α1-microglobulin (µg/gCr) r =0.734, P=1.32 × 10−15**
Notes: *P,0.05; **P,0.01. Spearman correlation coefficients are used.
Abbreviations: ACR, albumin/creatinine ratio; BMI, body mass index; Cr, serum 
creatinine; DPB, diastolic blood pressure; eGFR, estimated glomerular filtration 
ratio; HbA1c, hemoglobin A1c; HDL-C, HDL cholesterol; LDL-C, LDL cholesterol; 
SBP, systolic blood pressure; T-Cho, total cholesterol; TG, triglyceride; UN, 
serum urea nitrogen.
International Journal of Nephrology and Renovascular Disease 2013:6submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
236
Terami et al
0
0
100
r=0.376, P=3.84 × 10−4
200 300
Angiotensinogen
(µg/gCr)
A
A
C
R
 (
m
g
/g
C
r)
400
1,000
2,000
3,000
4,000
0
0
100
r=−0.350, P=1.02 × 10−3
200 300
Angiotensinogen
(µg/gCr)
B
eG
F
R
 (
m
L
/m
in
)
400
20
60
40
100
80
120
0
0
100
r=0.734, P=1.32 × 10−15
200 300
Angiotensinogen
(µg/gCr)
C
α
1-
m
ic
ro
g
lo
b
u
lin
(µ
g
/g
C
r)
400
20
40
60
80
0
0.5
100
r=−0.216, P=0.049
200 300
Angiotensinogen
(µg/gCr)
D
H
D
L
-C
 (
m
m
o
l/L
)
400
1.0
1.5
2.0
2.5
Figure 1 Simple correlation of urinary excretion of angiotensinogen with urinary ACR, eGFR, urinary α1-microglobulin, and HDL-C in patients with diabetic nephropathy 
(n=85). A, urinary ACR; B, eGFR; C, urinary α1-microglobulin; and D, HDL-C.
Note: Spearman correlation coefficients are used.
Abbreviations: ACR, albumin/creatinine ratio; eGFR, estimated glomerular filtration ratio; HDL-C, high-density lipoprotein cholesterol.
(Figure 2). By multiple regression analysis including all 
parameters (eGFR, ACR, and urinary α1-microglobulin) 
as independent variables, only urinary α1-microglobulin 
was a significant independent variable (Table 3, Model 1). 
Furthermore, in stepwise multiple regression analysis, only 
urinary α1-microglobulin was employed as an independent 
variable (Table 3, Model 2).
Urinary angiotensinogen  
and α1-microglobulin levels unaltered  
in RAS inhibitors (+) and (−) groups
We next compared various clinical parameters in the RAS 
inhibitors (+) and (−) groups. In RAS inhibitors (+), ACR 
was significantly higher compared with the RAS inhibitors 
(−) group (368.2 ± 863.8 versus 489.8 ± 779.8 mg/gCr, 
P=0.006). In contrast, there were no significant differences 
in urinary α1-microglobulin and angiotensinogen between 
the two groups (Figure 3). In clinical practice, type 2 diabetes 
patients with higher ACR seem to be preferentially treated 
with ARB or ACEI. Since urinary α1-microglobulin and 
angiotensinogen levels were not significantly higher in the 
RAS inhibitors (+) group, tubular damage and subsequent 
intrarenal RAS activation may be ameliorated by the admin-
istration of ARB or ACEI in RAS inhibitors (+) group.
Discussion
Proximal tubular angiotensinogen, collecting duct renin, and 
tubular angiotensin II type 1 receptors are positively aug-
mented by intrarenal angiotensin (Ang) II.4 The infusion of 
125I-Ang II into pigs demonstrated that steady-state concentra-
tions of 125I-Ang II in cortical and medullary tissue were four-
fold and twofold higher than arterial plasma and the tissue 
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concentrations of endogenous Ang II were 100 and 60 times 
higher than arterial plasma.5 Thus, it is suggested that most 
renal Ang II type 1 receptors are exposed to locally generated 
Ang II rather than Ang II from circulation. In rodent models, 
the urinary excretion of angiotensinogen in streptozotocin-
induced diabetic mice 3 days after the induction of diabetes 
was significantly higher (349.6 ± 89.1 µg/day) than control 
mice (15.9 ± 2.2 µg/day) and the authors demonstrated the 
upregulation of angiotensinogen messenger ribonucleic acid 
(mRNA) and protein expression in the mouse kidneys.6 The 
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Figure 2 Simple correlation of urinary excretion of angiotensinogen with urinary ACR and urinary α1-microglobulin in type 2 diabetes patients (n=85) in the normo- (n=36), 
micro- (n=25), and macroalbuminuric (n=24) stages.
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Table 3 Multiple linear regression analysis using urinary angiotensinogen as a dependent variable in patients with type 2 diabetes 
(n=85)
Dependent  
variable
Independent  
variable
Unstandardized  
coefficient
Standardized  
coefficient
t-value P-value Adjusted R2
B Standard error Beta
Model 1 
Urinary  
angiotensinogen  
(µg/gCr)
ACR (mg/gCr) 
eGFR (mL/min) 
Urinary α1- 
microglobulin (µg/gCr)
−0.001
0.022
3.647
0.007 
0.246 
0.498
0.014 
0.009 
0.728
0.142 
0.091 
7.324
0.888 
0.928 
1.58 × 10−10**
0.519
Model 2 
Urinary  
angiotensinogen  
(µg/gCr)
Urinary α1- 
microglobulin (µg/gCr)
3.668 0.374 0.732 9.800 1.64 × 10−15** 0.531
Notes: Estimated eGFR (mL/min), ACR (mg/gCr), and α1-microglobulin (µg/gCr) are used as independent variables in multiple linear regression analysis. In Model 1, all 
parameters are included; stepwise multiple linear regression analysis is performed in Model 2. **P,0.01.
Abbreviations: ACR, albumin/creatinine ratio; eGFR, estimated glomerular filtration ratio.
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data suggested that urinary excretion of angiotensinogen is 
a biomarker for the activation of RAS in the kidney under 
diabetic states. In humans, plasma angiotensinogen reaches 
urine via glomerular filtration, like albumin, and the normal 
urinary angiotensinogen levels in humans is ∼0.2 pmol/mL, 
versus ∼1,200 pmol/mL in plasma. Thus, the urinary angio-
tensinogen levels range from 0.01% to 0.1% of the plasma 
levels in humans. In contrast, urinary angiotensinogen levels 
in rodents are much higher and range from 0.1–400 pmol/mL, 
implying that the urinary angiotensinogen levels in rodents 
are sometimes higher than their plasma levels.1 Less than 
100-fold higher urinary angiotensinogen levels in rodents 
suggested the concept that urinary angiotensinogen is 
exclusively plasma-derived in humans, whereas it reflects 
angiotensinogen release from renal tissues, possibly proxi-
mal tubules, in rodents. Since albumin is produced in the 
liver and urinary albumin is entirely derived from plasma, 
the comparison of urinary albumin and angiotensinogen 
would demonstrate to what degree urinary angiotensinogen 
is plasma derived in humans. In fact, several studies2,7–9 
demonstrated high correlation between urinary albumin and 
angiotensinogen without exception.
In the current investigation, we simultaneously measured 
ACR, urinary α1-microglobulin, and urinary angiotensinogen 
levels in the patients with type 2 diabetes and various stages 
of diabetic nephropathy. Urinary angiotensinogen levels 
significantly and positively correlated with ACR (r=0.376, 
P=3.84 × 10−4) as previously reported, and we also found 
further high correlation with urinary α1-microglobulin 
(r=0.734, P=1.32 × 10−15). High correlation of urinary 
α1-microglobulin and angiotensinogen levels was also 
found both in microalbuminuria and microalbuminuria 
stages; however, ACR did not show significant correla-
tion with urinary angiotensinogen at normo-, micro-, and 
macroalbuminuria stages. The high correlation between 
urinary α1-microglobulin and angiotensinogen levels at the 
normoalbuminuric stage supported the concept that tubular 
damage promotes the intrarenal RAS activation and produc-
tion of tubular angiotensinogen, since the normoalbuminuric 
patients would not be expected to have leakage of plasma 
angiotensinogen into urinary space.
Urinary α1-microglobulin is filtered freely through 
glomerular capillaries and reabsorbed by the proximal 
tubules.10 Thus, urinary α1-microglobulin is a marker for 
proximal tubule dysfunction, and increased levels of urinary 
α1-microglobulin have been reported in normoalbuminuric 
patients with type 1 diabetes11,12 and type 2 diabetes.10,13,14 
The assessment of proximal tubule dysfunction in the course 
of diabetes by urinary α1-microglobulin allows the early 
diagnosis of diabetic nephropathy prior to the appearance 
of microalbuminuria, and also predicts the progression of 
diabetic nephropathy. Plasma angiotensinogen is filtered 
through glomerular capillaries, and urinary angiotensino-
gen is mainly derived from plasma. Subsequently, urinary 
angiotensinogen is largely removed via endocytotic uptake 
in tubules in a megalin-dependent manner. Endocytotic 
angiotensinogen is subsequently degraded and the contents 
of angiotensinogen in the proximal convoluted tubules highly 
correlated with plasma levels of angiotensinogen.15 Thus, 
previous studies also support the idea that urinary excretion 
of angiotensinogen reflects not only abnormalities of glom-
erular filtration barrier but also proximal tubular functions. 
It has been reported that urinary angiotensinogen levels 
increase before glomerular injuries in the patients16 as well 
as in rodents.6
Yamamoto et al demonstrated that administration of 
losartan reduced urinary and plasma angiotensinogen levels 
in the patients with chronic kidney disease.17 In hyperten-
sive patients with preserved kidney function, RAS blockers 
decreased the urinary angiotensinogen, and the decrease 
was comparable to that in urinary albumin7. Furthermore, 
in immunoglobulin A nephropathy, treatment with valsar-
tan also reduced urinary angiotensinogen.18,19 As in various 
kidney diseases, RAS inhibitors suppressed urinary angio-
tensinogen levels with type 2 diabetes.20 One can speculate 
that reduction of urinary angiotensinogen by RAS blockers 
is due to the amelioration of glomerular hyperfiltration 
and suppression of enhanced filtration of various proteins, 
including angiotensinogen, through glomerular capillaries. 
Although ACR was higher in the RAS inhibitors (+) group, 
urinary α1-microglobulin and angiotensinogen were not 
significantly increased in the RAS inhibitors (+) group. Thus, 
we speculate that RAS inhibitors may ameliorate the tubular 
injuries and intrarenal RAS activation, which was reflected by 
the lack of significant increase in urinary α1-microglobulin 
and angiotensinogen levels.
Conclusion
In summary, we demonstrated the significant and positive 
correlation of urinary angiotensinogen levels with ACR 
and urinary α1-microglobulin, and the negative correlation 
with eGFR. In a multiple regression analysis including all 
parameters (eGFR, ACR and urinary α1-microglobulin) as 
independent variables, only urinary α1-microglobulin was a 
significant independent variable. The current cross-sectional 
clinical study revealed that urinary angiotensinogen is a marker 
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for tubular injuries of the early stage of diabetic nephropathy 
in patients with type 2 diabetes. Since the current study was 
a cross-sectional clinical investigation, the significance of 
urinary angiotensinogen for predicting long-term course of 
diabetic nephropathy is still unknown. In future studies, the 
significance of urinary angiotensinogen in predicting the pro-
gression of diabetic nephropathy needs to be demonstrated.
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